Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Andreas Schnapp

Thierry Bouyssou

Ingo Konetzki

Christoph Hoenke

Philipp Lustenberger

Klaus Rudolf

Kurt Schromm

Sabine Pestel

Frank Buettner

Claudia Heine

Hermann Schollenberger

Matthias Hoffmann

Dennis Fiegen

Norbert Hauel

Henning Priepke

Sandra Handschuh

Juergen Mack

Klaus Damm

Georg Dahmann

Marco Santagostino

Dieter Wiedenmayer

Jasna Klicic

Guenter Linz

Gerhard Schaenzle

Annette Schuler-Metz

Edward Walker

Michael Philip Mazanetz

Silke Hobbie

Takeshi Kono

Robert John Scott

Yayoi Sato

Matthias Grauert

Georg Speck

Horst Dollinger

Michael Paul Pieper

Steffen Breitfelder

Enzo Cereda

Christian Gnamm

Steffen Steurer

Iris Kauffmann-Hefner

Matthias Treu

Michel Pairet

Stephen East

Ulrike Weyer-Czernilofsky

Maria Impagnatiello

Bernd Krist

Pilar Garin-Chesa

David James Lamb

Stephen Peter East

Darryl McConnel

Phillip Lustenberger

Pilar Garin-chesa

Darryl Mcconnell

Stephen P East

Jürgen Mack

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein wherein n is either 0 or 1,

Substituted naphthyridines and their use as medicaments

The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula 1 whereinR, R, R, Rand Rare defined as in claimand pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.

Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein

4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments

The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, Rcan represent a group A selected from among the group comprising &#x2014;O&#x2014;R, &#x2014;NRR, &#x2014;CRRR, -(ethyne)-R, &#x2014;S&#x2014;R, &#x2014;SO&#x2014;R, and SO&#x2014;R, or Rrepresents a group B selected from among the group comprising: &#x2014;C-aryl; &#x2014;a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom; &#x2014;a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and &#x2014;a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims, and R, R, R, R, and m can have the meanings indicated in claim. The invention also relates to pharmaceutical compositions containing said compounds. 

A pharmaceutical composition comprising a compound of formula 1 wherein:

Medicaments for the treatment of chronic obstructive pulmonary disease

The invention relates to compounds of general formula 1 wherein n, A, B, D, L, R, R, Rand Rmay have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Long acting bronchodilators for the treatment of respiratory diseases

The invention relates to pyrrolobenzimidazolone compounds of formula (I), wherein A, T and Rto Rare defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.

Pyrrolobenzimidazolones and their use as anti-proliferative agents

A compound of formula 1'&#x2033; wherein:

Long acting beta-2-agonists and their use as medicaments

The present invention relates to compounds of formula 1 wherein the groups R, R, R, R, R, R, R, R, n, m and X may have the meanings given in the claims and in the specification, and the use thereof as pharmaceutical compositions, particularly for the treatment of inflammatory and obstructive respiratory complaints.

Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament

The present invention relates to the use of the compounds of general formula 1 wherein the groups R, X and Y may have the meanings given in the claims and in the specification, for preparing a pharmaceutical composition for the treatment of COPD (chronic obstructive pulmonary disease), as well as new compounds of general formula 1 and processes for preparing them.

3-hydroxymethyl-4-hydroxy-phenyl-derivatives for the treatment of respiratory diseases

The present invention relates to compounds of formula 1 wherein the groups n, m, B, X and Rmay have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Betamimetics for the treatment of respiratory complaints

The present invention relates to compounds of formula 1, wherein n, A, R, Rand Rmay have the meanings specified in the description and claims, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Long-acting betamimetics for the treatment of respiratory complaints

Growing community of inventors

Biberach, Germany

Andreas Schnapp